US2681582019
© BusinessWire
24.12.2025
DVAX
LISTED
NASDAQ
DVAX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Dynavax Technologies Corporation is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Dynavax Technologies Corporation (NASDAQ: DVAX) to Sanofi for $15.50 per share in cash is fair to Dynavax shareholders.
Halper Sadeh encourages Dynavax shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachar...
Themefolio
Profiler
Peergroup
© PR Newswire
24.12.2025
DVAX
LISTED
NASDAQ
Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline
News Preview
Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price onDecember 23, 2025EMERYVILLE, Calif., Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Nasdaq: DVAX), a publicly traded vaccines company with a marketed adult hepatitis...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2025
DVAX
LISTED
NASDAQ
Dynavax to Participate at the 8th Annual Evercore Healthcare Conference
News Preview
EMERYVILLE, Calif., Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
05.11.2025
DVAX
LISTED
NASDAQ
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
News Preview
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r
eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million
Board of Directors authorizes new $100...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
05.11.2025
DVAX
LISTED
NASDAQ
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
News Preview
Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options
Vaxart to continue leading and funding development...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
DVAX
LISTED
NASDAQ
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025
News Preview
EMERYVILLE, Calif., Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets clos...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
DVAX
LISTED
NASDAQ
Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial
News Preview
Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile
Newly presented data outline robust polyfunctional CD4+ T-cell responses in Z-1018 arms...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2025
DVAX
LISTED
NASDAQ
Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference
News Preview
EMERYVILLE, Calif., Aug. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd at 4:30 p...
Themefolio
Profiler
Peergroup
© PR Newswire
07.08.2025
DVAX
LISTED
NASDAQ
Dynavax Reports Second Quarter 2025 Financial Results
News Preview
Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growthRefines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 millionTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025Completed dosing in Part 1 of Phase 1/2...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
DVAX
LISTED
NASDAQ
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
News Preview
EMERYVILLE, Calif., July 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2025 financial results on Thursday, August 7, 2025, after the U.S. financial markets close....
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2025
DVAX
LISTED
NASDAQ
Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting
News Preview
EMERYVILLE, Calif., June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2025 Annu...
Themefolio
Profiler
Peergroup
© BusinessWire
09.06.2025
DVAX
LISTED
NASDAQ
Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
News Preview
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company’s outstanding shares, today issued a letter to shareholders detailing the benefits of electing D...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
09.06.2025
DVAX
LISTED
NASDAQ
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
News Preview
Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value
Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area
Follow Recommendations of Proxy Advisory Firms ISS and Egan-Jones and Vote "FOR" All Four of Dynavax's Director Nominees on the GOLD Proxy Card Today
EMERYVILLE, Calif., June 9, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
04.06.2025
DVAX
LISTED
NASDAQ
Dynavax Comments on Glass Lewis Recommendation
News Preview
Dynavax is Already Delivering Significant Long Term Stockholder Value Through Execution of Current Strategy Overseen by Board; Deep Track's Inferior Short-Term Plan and Nominees are Not in the Best Interests of All Stockholders
Glass Lewis' Recommendation Recognizes the Significant Stockholder Value Creation and Differentiated Capital Return Ove...
Themefolio
Profiler
Peergroup
© BusinessWire
04.06.2025
DVAX
LISTED
NASDAQ
Glass Lewis Recommends Shareholders Support Deep Track’s Case for Board Change at Dynavax Technologies
News Preview
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company’s outstanding shares, today announced that leading independent proxy advisory firm Glass, Lewis...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
DVAX
LISTED
NASDAQ
Dynavax to Present at William Blair's 45th Annual Growth Stock Conference
News Preview
EMERYVILLE, Calif., May 28, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at William Blair's 45th Annual Growth Stock Conference on Tuesday, June 3rd at 2:40 p.m. CT....
Themefolio
Profiler
Peergroup
© BusinessWire
24.05.2025
DVAX
LISTED
NASDAQ
Deep Track Capital Comments on ISS Recommendation
News Preview
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company’s outstanding shares, today issued the following statement in response to a report issued by Ins...
Themefolio
Profiler
Peergroup
© PR Newswire
23.05.2025
DVAX
LISTED
NASDAQ
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees
News Preview
ISS Recognizes There is No Case for Change
Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value
Dynavax Comments on Deep Track's Misleading Supplemental Materials
Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
DVAX
LISTED
NASDAQ
Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting
News Preview
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company’s outstanding shares, today issued a letter to shareholders in connection with its nomination of...
Themefolio
Profiler
Peergroup
© PR Newswire
12.05.2025
DVAX
LISTED
NASDAQ
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value
News Preview
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today
EMERYVILLE, Calif., May 12, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage bio...
Themefolio
Profiler
Peergroup
© PR Newswire
10.05.2025
DVAX
LISTED
NASDAQ
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
News Preview
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today
EMERYVILLE, Calif., May 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq:...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
DVAX
LISTED
NASDAQ
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
News Preview
Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growthTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively Conference call...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
DVAX
LISTED
NASDAQ
Deep Track Capital Releases Investor Presentation on Dynavax Technologies
News Preview
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.53% of the Company’s outstanding shares, today released an investor presentation titled “The Path to Creating and Pr...
Themefolio
Profiler
Peergroup
© PR Newswire
01.05.2025
DVAX
LISTED
NASDAQ
Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits
News Preview
Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatitis B virusFindings released during Hepatitis Awareness Month underscore the importance of public education to address misunderstandings about hepatit...
Themefolio
Profiler
Peergroup
© PR Newswire
29.04.2025
DVAX
LISTED
NASDAQ
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
News Preview
Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card
EMERYVILLE, Calif., April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, t...
Themefolio
Profiler
Peergroup
© PR Newswire
22.04.2025
DVAX
LISTED
NASDAQ
Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
News Preview
EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close....
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
DVAX
LISTED
NASDAQ
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
News Preview
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.53% of the Company’s outstanding shares, today announced that it has filed a definitive proxy statement in connecti...
Themefolio
Profiler
Peergroup
© PR Newswire
17.04.2025
DVAX
LISTED
NASDAQ
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
News Preview
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card
Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board Refreshment
Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy Contest
EMERYVILLE, Calif., April 17, 2025 /PRNewswi...
Themefolio
Profiler
Peergroup
© BusinessWire
16.04.2025
DVAX
LISTED
NASDAQ
Deep Track Capital Comments on Dynavax Technologies’ Rejection of Most Recent Settlement Offer
News Preview
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.34% of the Company’s outstanding shares. Today Deep Track commented on the Company’s disclosure that the Board of...
Themefolio
Profiler
Peergroup
© PR Newswire
03.04.2025
DVAX
LISTED
NASDAQ
Dynavax Files Preliminary Proxy Statement
News Preview
Dynavax's Board is Overseeing Record Operational and Financial Performance
Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution
EMERYVILLE, Calif., April 3, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
DVAX
LISTED
NASDAQ
Deep Track Capital Sends Letter to Dynavax Technologies’ Board of Directors
News Preview
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.34% of the Company’s outstanding shares, today sent a letter to the Company’s Board of Directors (the “Board”) rela...
Themefolio
Profiler
Peergroup
© PR Newswire
06.03.2025
DVAX
LISTED
NASDAQ
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
News Preview
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure$225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new moneyDynavax repurchased ~$8...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
DVAX
LISTED
NASDAQ
Dynavax to Participate in Upcoming Investor Conferences
News Preview
EMERYVILLE, Calif., Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
DVAX
LISTED
NASDAQ
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
News Preview
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025Top-line results in Phase 1/2 shingles trial expected in Q3 2025Plan to initiate Phase 2 trial for plague vaccine in Q3 2025Expect completion of $200 million share repurchase program in 2025Conference call t...
Themefolio
Profiler
Peergroup
© PR Newswire
19.02.2025
DVAX
LISTED
NASDAQ
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy
News Preview
Reiterates Meaningful Board Change Already Underway
EMERYVILLE, Calif., Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
DVAX
LISTED
NASDAQ
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting
News Preview
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 13.53% of the Company’s outstanding shares, today announced that it has nominated four highly qualified candidates for...
Themefolio
Profiler
Peergroup
© PR Newswire
06.02.2025
DVAX
LISTED
NASDAQ
Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025
News Preview
EMERYVILLE, Calif., Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the U.S. financial markets close....
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2025
DVAX
LISTED
NASDAQ
Dynavax Advances Board Refreshment Program
News Preview
Appoints Emilio Emini and Lauren Silvernail to Board of Directors; Two Directors to Step Down at 2025 Annual Meeting
Intends to Seek Stockholder Approval for Declassification of Board at 2025 Annual Meeting
EMERYVILLE, Calif., Jan. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) (the "Company"), a commercial-stage biophar...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
DVAX
LISTED
NASDAQ
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
News Preview
Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 millionEnrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025New $30 million contract with U.S. Department of Defense to advance plague vaccine programCash, cash equivalents and marketable securities were approximately $7...
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2024
DVAX
LISTED
NASDAQ
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
News Preview
EMERYVILLE, Calif., Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m. ET....
Themefolio
Profiler
Peergroup
© PR Newswire
11.11.2024
DVAX
LISTED
NASDAQ
Dynavax Announces $100 Million Accelerated Share Repurchase Program
News Preview
EMERYVILLE, Calif., Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repu...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
DVAX
LISTED
NASDAQ
Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates
News Preview
HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-over-year growthHepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market shareExpect positive net income in 2024, achieving full year profitability Strengthene...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
DVAX
LISTED
NASDAQ
Dynavax Announces $200 Million Share Repurchase Program
News Preview
EMERYVILLE, Calif., Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced its Board of Directors has authorized the repurchase of up to $200 million of the Company's common stock. The share repurchase program do...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
DVAX
LISTED
NASDAQ
Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)
News Preview
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Dynavax Technologies Corporation (Nasdaq: DVAX) concerning the Company and its directors’ and officers’ possible violations of state laws.
If you own Dynavax stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights o...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
DVAX
LISTED
NASDAQ
Dynavax Adopts Limited-Duration Stockholder Rights Plan
News Preview
EMERYVILLE, Calif., Oct. 29, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan")....
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
DVAX
LISTED
NASDAQ
Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
News Preview
EMERYVILLE, Calif., Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
